June 7 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
VRX.TO :
* Updating its full year 2016 guidance
* FY adjusted ebitda (non-gaap) is expected to be in range
of $4.80 - $4.95 billion
* FY 2016 earnings per share view $8.46, revenue view $10.86
billion -- Thomson Reuters I/B/E/S
* "We have made progress toward stabilizing organization
over past few months"
* While we recognize that we did not meet timeline for
filing Q1 results, with filing expected this week, we will be
current in our financial reporting
* "Expect to file our financial results in a timely manner
going forward"
* "There are some challenges to work through in certain
business operations in 2016, such as our u.s. Dermatology unit"
* Full year 2016 total revenue guidance updated from
previous guidance of $11.0 - $11.2 billion
* Full year 2016 adjusted eps (non-gaap) guidance updated
from previous guidance of $8.50 - $9 .50
* Q1's results reflect, in part, impact of "significant
disruption" this organization has faced over past nine months
* "There are some challenges to work through in certain
business operations in 2016"
* "Majority of our businesses are performing according to
expectations"
* Valeant pharmaceuticals reports first quarter 2016
financial results
* Sees FY 2016 adjusted non-gaap earnings per share $6.60 to
$7.00
* Q1 adjusted non-gaap earnings per share $1.27
* Q1 gaap loss per share $1.08
* Sees FY 2016 revenue $9.9 billion to $10.1 billion
* Q1 revenue $2.4 billion versus i/b/e/s view $2.38 billion
* Q1 earnings per share view $1.37 -- Thomson Reuters
I/B/E/S
Source text for Eikon: ID:nCNWZ4HvDa
Further company coverage: VRX.TO
(Bengaluru Newsroom: +1-646-223-8780)